Results 41 to 50 of about 23,474 (264)

On separable Schr\"odinger equations

open access: yes, 1999
We classify (1+3)-dimensional Schr\"odinger equations for a particle interacting with the electromagnetic field that are solvable by the method of separation of variables. As a result, we get eleven classes of the electromagnetic vector potentials of the
Alexander Zhalij   +4 more
core   +2 more sources

Oncolytic herpes viruses, chemotherapeutics, and other cancer drugs [PDF]

open access: yes, 2013
Oncolytic viruses are emerging as a potential new way of treating cancers. They are selectively replication-competent viruses that propagate only in actively dividing tumor cells but not in normal cells and, as a result, destroy the tumor cells by ...
Braidwood, L.   +3 more
core   +1 more source

Some Exact Blowup Solutions to the Pressureless Euler Equations in R^N

open access: yes, 2009
The pressureless Euler equations can be used as simple models of cosmology or plasma physics. In this paper, we construct the exact solutions in non-radial symmetry to the pressureless Euler equations in $R^{N}:$% [c]{c}% \rho(t,\vec{x})=\frac{f(\frac{1}{
Berthon   +23 more
core   +1 more source

A phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancer

open access: yesScientific Reports, 2021
Talimogene laherparepvec (T-VEC) is an immunotherapy that generates local tumor lysis and systemic antitumor immune response. We studied the efficacy of intratumoral administration of T-VEC as monotherapy for inoperable locoregional recurrence of breast ...
Megumi Kai   +13 more
doaj   +1 more source

High response rates for T‐VEC in early metastatic melanoma (stage IIIB/C‐IVM1a) [PDF]

open access: yesInternational Journal of Cancer, 2019
Talimogene laherparepvec (T‐VEC) is a modified herpes simplex virus, type 1 (HSV‐1), which can be administered intralesionally in patients with stage IIIB/C‐IVM1a unresectable melanoma (EMA label). The phase 3 OPTiM registration study showed an overall response rate (ORR) of 26%.
Viola Franke   +8 more
openaire   +2 more sources

Biological therapy in the treatment of melanoma [PDF]

open access: yes, 2018
Melanoma is one of the most aggressive tumors and its incidence is on the rise. The low rates of survival in metastatic melanoma has led to the development of new drugs for this type of patient, such as biological therapy which has shown remarkable ...
Benea, Vasile   +8 more
core   +3 more sources

Covariance Estimation in High Dimensions via Kronecker Product Expansions [PDF]

open access: yes, 2013
This paper presents a new method for estimating high dimensional covariance matrices. The method, permuted rank-penalized least-squares (PRLS), is based on a Kronecker product series expansion of the true covariance matrix. Assuming an i.i.d.
Alfred O. Hero Iii   +2 more
core   +1 more source

Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors

open access: yesOncoImmunology, 2018
Oncolytic viruses selectively target and kill cancer cells in an immunogenic fashion, thus supporting the establishment of therapeutically relevant tumor-specific immune responses. In 2015, the US Food and Drug Administration (FDA) approved the oncolytic
Jonathan G. Pol   +14 more
doaj   +1 more source

Vascular endothelial‐cadherin as a marker of endothelial injury in preclinical Alzheimer disease

open access: yesAnnals of Clinical and Translational Neurology, 2022
Objective Endothelial dysfunction is an early and prevalent pathology in Alzheimer disease (AD). We here investigate the value of vascular endothelial‐cadherin (VEC) as a cerebrospinal fluid (CSF) marker of endothelial injury in preclinical AD.
Rawan Tarawneh   +5 more
doaj   +1 more source

Fluctuation-dissipation theorem for thermo-refractive noise

open access: yes, 2007
We introduce a simple prescription for calculating the spectra of thermal fluctuations of temperature-dependent quantities of the form $\hat{\delta T}(t)=\int d^3\vec{r} \delta T(\vec{r},t) q(\vec{r})$.
Abramovici   +9 more
core   +1 more source

Home - About - Disclaimer - Privacy